<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Nivolumab: Indications, Adverse Effects, Contraindications and Dosage</title>
  <meta charset="utf-8">
  
  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="Nivolumab, metastatic urothelial carcinoma, renal cell carcinoma, adjuvant therapy" >
<meta name="description" content="Pharmacology, adverse effects and contraindications of Nivolumab, from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> 
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><span style="font-size: 1.2em;">Urology Textbook</span><br>
       
       <span style="font-size: 0.8em;">Clinical Essentials</span>
       <br>
       <span style="font-size: 0.6em;">By Dirk Manski, MD</span></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>

</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Nivolumab</p>

<h1>Nivolumab: Mechanism of Action, Adverse Effects, Contraindications and Dosage</h1>

<h2>Mechanism of Action of Nivolumab</h2>
<p>Nivolumab is a monoclonal antibody directed against the programmed cell death–1 (PD-1) receptor. By inhibiting this immune checkpoint, nivolumab enhances T-cell–mediated immunity against advanced cancer.</p>

<h2>Treatment of Advanced Renal Cell Carcinoma with Nivolumab</h2>
<p>Nivolumab is approved for first-line therapy of <a href="https://www.urology-textbook.com/renal-cell-carcinoma-targeted-therapy.html">metastatic renal cell carcinoma</a> in combination with cabozantinib (all risk groups) and in combination with ipilimumab for patients with poor prognosis. Nivolumab is also approved as second-line therapy.</p>
<ul>
  <li>First-line therapy of metastatic renal cell carcinoma with <strong>Nivolumab and cabozantinib:</strong> In the CheckMate-9ER trial, the combination improved progression-free survival (17 vs. 8 months; HR 0.51), overall response rate (56% vs. 27%), complete response (8% vs. 5%), and overall survival (HR 0.60) versus sunitinib, with benefit across all risk groups (Choueiri et&nbsp;al., 2021).</li>
  <li>First-line therapy of metastatic renal cell carcinoma with <strong>Nivolumab and ipilimumab:</strong> In CheckMate-214, the combination showed superior progression-free and overall survival compared with sunitinib in first-line therapy for patients with intermediate and poor risk (overall survival 56 vs. 38 months at 5-year follow-up). The regimen also demonstrated strong activity in sarcomatoid renal cell carcinoma (Albiges et&nbsp;al., 2020).</li>
  <li>Second-line therapy of metastatic renal cell carcinoma with <strong>Nivolumab monotherapy:</strong> As second-line therapy after tyrosine kinase inhibitor failure, nivolumab improved progression-free survival, response rate (CR + PR: 25% vs. 5%), and overall survival (25 vs. 20 months) versus everolimus, with fewer adverse effects (Motzer et&nbsp;al., 2015).</li>
</ul>

<h2>Treatment of Advanced Urothelial Carcinoma with Nivolumab</h2>
<p>Nivolumab is approved as first-line therapy of <a href="https://www.urology-textbook.com/bladder-cancer-chemotherapy.html">metastatic urothelial (bladder) carcinoma</a> in combination with Cisplatin-Gemcitabine chemotherapy, for second-line therapy of metastatic urothelial carcinoma after platinum-containing chemotherapy and for adjuvant therapy <a href="https://www.urology-textbook.com/radical-cystectomy.html">after cystectomy</a>.</p>

<ul>
    <li>First-line therapy of metastatic urothelial (bladder) carcinoma with Nivolumab and cisplatin-gemcitabine chemotherapy (GC+N): The combination GC+N was tested in a phase III trial (CheckMate 901) as first-line therapy against GC (Heijden et al., 2023): Overall survival 22 vs. 19 months, complete remission 22% vs. 12%, grade 3&ndash;5 adverse events were 62% vs. 52%. </li>
    <li>Second-line therapy of metastatic urothelial (bladder) carcinoma with nivolumab after progression with platinum-based chemotherapy: objective response rate 20–26%, with median overall survival 9–10 months (Sharma et al., 2016; Sharma et al., 2017).</li>
    <li>Adjuvant therapy after cystectomy: In patients at high risk of recurrence (pT3&ndash;4 or pN+), nivolumab improved disease-free survival after cystectomy: 21 months (nivolumab) vs. 11 months (placebo) (Bajorin et&nbsp;al., 2021). In Europe, approval was restricted to patients with tumor-cell PD-L1 expression &ge;1%.</li>
</ul>

<h2>Pharmacokinetics of Nivolumab</h2>
<p>Administer by intravenous infusion over 30&ndash;60 min. The elimination half-life is approximately 26 days. Catabolic protein metabolism mediates clearance.</p>

<h2>Adverse Effects of Nivolumab</h2>
<p>Nivolumab is associated with immune-mediated adverse events, which can occur up to five months after the last dose. Depending on severity, clinicians should hold or discontinue nivolumab and initiate corticosteroids (typically methylprednisolone 1–3&nbsp;mg/kg/day), followed by a taper. See also the section on adverse effects of immune checkpoint inhibition.</p>
<ul>
  <li><strong>Immune system:</strong> Infusion-related reactions; infrequent anaphylaxis or vasculitis.</li>
  <li><strong>Pneumonitis (~3%):</strong> Radiographic changes, dyspnea, and hypoxemia.</li>
  <li><strong>Colitis (~13%):</strong> Abdominal pain, diarrhea, mucus or blood in stool.</li>
  <li><strong>Hepatitis (~7%):</strong> Elevated transaminases and bilirubin.</li>
  <li><strong>Nephritis (~3%):</strong> Increased serum creatinine.</li>
  <li><strong>Endocrinopathies (~8%):</strong> Hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes mellitus, and diabetic ketoacidosis.</li>
  <li><strong>Dermatologic (≈28%):</strong> From mild exanthems to toxic epidermal necrolysis or Stevens–Johnson syndrome.</li>
  <li><strong>Hematologic:</strong> Anemia ~4%, neutropenia ~0.5%.</li>
  <li><strong>Rare (&lt;1%):</strong> Pancreatitis, uveitis, demyelination, autoimmune neuropathy, Guillain–Barré syndrome, pituitary insufficiency, and myasthenic syndromes.</li>
</ul>

<h3>Contraindications to Nivolumab</h3>
<p>Loss of clinical benefit or unequivocal disease progression; grade 4 immune-mediated adverse events; persistent grade 2/3 adverse events despite treatment interruption and corticosteroids. Pregnancy and lactation.</p>

<h2>Drug Interactions with Nivolumab</h2>
<p>Systemic corticosteroids and other immunosuppressants may blunt nivolumab’s pharmacodynamic activity and should be avoided unless clinically necessary to manage immune-mediated toxicity.</p>
<p>There is a complex interplay between the gut microbiome and the activity of immune checkpoint inhibitors. Exposure to systemic antibiotics around the start of therapy has been associated in multiple observational studies with reduced efficacy of checkpoint inhibitors.</p>

<h2>Dosing of Nivolumab Monotherapy</h2>
<p>Administer 240&nbsp;mg every two weeks as a short infusion (about 30 minutes) or 480&nbsp;mg every four weeks as a short infusion (about 60 minutes, depending on institutional practice).</p>

<h2>Dosing of Nivolumab in Combination with Ipilimumab</h2>
<p>Administer nivolumab 1&nbsp;mg/kg combined with ipilimumab 3&nbsp;mg/kg intravenously every three weeks for four cycles. Continue with nivolumab monotherapy afterward using the dosing above.</p>

<h4>Monitoring During Therapy with Nivolumab</h4>
<p>See also the section on adverse effects of immune checkpoint inhibition. Perform regular monitoring of complete blood count; electrolytes; liver function tests; lipase; coagulation parameters; blood glucose; creatinine; thyroid function; skin; neurologic status; oral mucosa; and blood pressure. Before each cycle, assess for symptoms and laboratory abnormalities.</p>
<p>Educate the patient about potential adverse effects across organ systems to ensure prompt reporting, timely evaluation, treatment interruption or discontinuation, and corticosteroid initiation when indicated.</p>



<br>
<br><div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
<td><a href="https://www.urology-textbook.com/atezolizumab.html">Atezolizumab</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index.html">Index</a></td>
<td><a href="https://www.urology-textbook.com/pembrolizumab.html">Pembrolizumab</a></td>
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<h3>References</h3>

<p>L. Albiges, N. M. Tannir, M. Burotto, D. McDermott, E. R. Plimack, and R. J. Motzer, “Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.,” <i>ESMO open</i>, vol. 5, no. 6, p. e001079, 2020.</p>

   
<p>D. F. Bajorin et al., “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.,” NEJM, vol. 384, no. 22, pp. 2102–2114, 2021, doi: 10.1056/NEJMoa2034442.</p>
  
 

<p>Motzer, R. J.; Escudier, B.; McDermott, D. F.; George, 
        S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, 
        G.; Plimack, E. R.; Castellano, D.; Choueiri, T. K.; Gurney, H.; Donskov, 
        F.; Bono, P.; Wagstaff, J.; Gauler, T. C.; Ueda, T.; Tomita, Y.; Schutz, 
        F. A.; Kollmannsberger, C.; Larkin, J.; Ravaud, A.; Simon, J. S.; Xu, 
        L.-A.; Waxman, I. M.; Sharma, P. &amp; CheckMate025
        Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.<br><b>New Engl J Med 2015</b><i>, 373</i>, 
        1803-1813.</p>
    
    <br>

<p>Sharma, P.; Callahan, M. K.; Bono, P.; Kim, J.; 
        Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; de Braud, F.; 
        Morse, M.; Le, D. T.; Jaeger, D.; Chan, E.; Harbison, C.; Lin, C.-S.; 
        Tschaika, M.; Azrilevich, A. &amp; Rosenberg, J. E.
        Nivolumab 
        monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): 
        a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.<br><em>The 
        Lancet. Oncology, </em><b>2016</b><i>, 17</i>, 1590-1598.</p>

 
<p>Sharma, P.; Retz, M.; Siefker-Radtke, A.; Baron, 
        A.; Necchi, A.; Bedke, J.; Plimack, E. R.; Vaena, D.; Grimm, M.-O.; 
        Bracarda, S.; Arranz, J. &#193;.; Pal, S.; Ohyama, C.; Saci, A.; Qu, X.; 
        Lambert, A.; Krishnan, S.; Azrilevich, A. &amp; Galsky, M. D.
        Nivolumab 
        in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): 
        a multicentre, single-arm, phase 2 trial.<br><em>The Lancet. Oncology, </em><b>2017</b><i>, 
        18</i>, 312-322.</p>


<br>
<br>

<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/nivolumab.html">Nivolumab</a></p>

<h3>Urology-Textbook.com – Choose the Ad-Free, Professional Resource</h3>
<p>This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? <a href="https://steady.page/de/urology/about">Join Steady to unlock full access</a> to all images and enjoy an ad-free experience. Try it free for 7 days&mdash;no obligation. </p>

<p><strong>New release:</strong> The first edition of the Urology Textbook as an e-book&mdash;ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.</p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
	
<img src="https://vg08.met.vgwort.de/na/5d52ef64c3dd48aa9cc8b044b68924e4" width="1" height="1" alt="">


</footer>
</body>
</html>
